Crews, Craig M.

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 3,395

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 2,609

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,486

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,356

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,140

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

Burslem, G. M., & Crews, C. M. (2020) · Cell

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 1,079

Targeted protein degradation: expanding the toolbox

Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 960

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 923

PROTACs: past, present and future

Li, K., & Crews, C. M. (2022) · Chemical Society Reviews

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 869

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 852

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 686

Small‐Molecule PROTACS: New Approaches to Protein Degradation

Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 674

Protein degraders enter the clinic — a new approach to cancer therapy

Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 658

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsProstate Cancer Treatment and Research

Cited by 635

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 618

Targeted protein degradation by PROTACs

Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 599

Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction

Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 569

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 517

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins

Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 488

Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs

Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 450

Structure of Human Methionine Aminopeptidase-2 Complexed with Fumagillin

Liu, S., Widom, J., Kemp, C. W., Crews, C. M., & Clardy, J. (1998) · Science

Enzyme Structure and FunctionPeptidase Inhibition and Analysis

Cited by 440

Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins

Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 429

Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation

Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 425

Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation

Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 394